Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma

Abstract excerpt

PURPOSE: Minimal residual disease (MRD) presents a significant hurdle to curing metastatic neuroblastoma. Biological therapies directed against MRD can improve outcome. Evaluating treatment efficacy requires MRD measurement, which serves as surrogate endpoint. Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Hypoxia, and Metabolism
• Share to Cancer-related gene regulation
• Share to Neuroblastoma Research and Treatments